NEO
Price:
$16.39
Market Cap:
$2.10B
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
2004-03-16
Stock Exchange
NASDAQ
Ticker
NEO
According to NeoGenomics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -26.87. This represents a change of 3.79% compared to the average of -25.89 of the last 4 quarters.
The mean historical PE Ratio of NeoGenomics, Inc. over the last ten years is 75.94. The current -26.87 PE Ratio has changed -3638.30% with respect to the historical average. Over the past ten years (40 quarters), NEO's PE Ratio was at its highest in in the December 2018 quarter at 832.96. The PE Ratio was at its lowest in in the June 2017 quarter at -4136.86.
Average
75.94
Median
-15.52
Minimum
-818.60
Maximum
1.40K
Discovering the peaks and valleys of NeoGenomics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 609.58%
Maximum Annual PE Ratio = 1.40K
Minimum Annual Increase = -195.37%
Minimum Annual PE Ratio = -818.60
Year | PE Ratio | Change |
---|---|---|
2023 | -23.08 | 190.11% |
2022 | -7.96 | -98.38% |
2021 | -490.37 | -135.00% |
2020 | 1.40K | 281.73% |
2019 | 367.07 | -16.07% |
2018 | 437.38 | -153.43% |
2017 | -818.60 | 609.58% |
2016 | -115.36 | -38.60% |
2015 | -187.91 | -195.37% |
2014 | 197.02 | 129.26% |
The current PE Ratio of NeoGenomics, Inc. (NEO) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-173.80
5-year avg
249.38
10-year avg
75.94
NeoGenomics, Inc.’s PE Ratio is greater than Natera, Inc. (-96.43), less than Qiagen N.V. (102.34), greater than Neogen Corporation (-137.94), less than Guardant Health, Inc. (-7.84), less than CareDx, Inc (-8.52), less than Myriad Genetics, Inc. (-7.14), less than Invitae Corporation (-0.00), less than Castle Biosciences, Inc. (136.61), less than Syneos Health, Inc. (16.61), less than Mettler-Toledo International Inc. (32.59), less than ICON Public Limited Company (23.73), less than IQVIA Holdings Inc. (26.16), less than Charles River Laboratories International, Inc. (24.36), less than Sotera Health Company (51.29), greater than Olink Holding AB (publ) (-96.25), less than Aclaris Therapeutics, Inc. (-7.33), less than Twist Bioscience Corporation (-11.85), less than Biodesix, Inc. (-4.27),
Company | PE Ratio | Market cap |
---|---|---|
-96.43 | $22.08B | |
102.34 | $9.49B | |
-137.94 | $3.25B | |
-7.84 | $4.03B | |
-8.52 | $1.24B | |
-7.14 | $1.41B | |
-0.00 | $5.44M | |
136.61 | $834.90M | |
16.61 | $4.46B | |
32.59 | $25.70B | |
23.73 | $17.69B | |
26.16 | $36.63B | |
24.36 | $10.01B | |
51.29 | $3.63B | |
-96.25 | $3.24B | |
-7.33 | $271.44M | |
-11.85 | $2.51B | |
-4.27 | $186.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeoGenomics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeoGenomics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NeoGenomics, Inc.'s PE Ratio?
How is the PE Ratio calculated for NeoGenomics, Inc. (NEO)?
What is the highest PE Ratio for NeoGenomics, Inc. (NEO)?
What is the 3-year average PE Ratio for NeoGenomics, Inc. (NEO)?
What is the 5-year average PE Ratio for NeoGenomics, Inc. (NEO)?
How does the current PE Ratio for NeoGenomics, Inc. (NEO) compare to its historical average?